Current methods of protein detection are insensitive to detecting subtle changes in oncoprotein activation that underlie key cancer signaling processes. The requirement for large numbers of cells precludes serial tumor sampling for assessing a response to therapeutics. Therefore, we have developed a nanofluidic proteomic immunoassay (NIA) to quantify total and low-abundance protein isoforms in nanoliter volumes. Our method can quantify amounts of MYC oncoprotein and B cell lymphoma protein-2 (BCL2) in Burkitt's and follicular lymphoma; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, mitogen-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in imatinib-treated chronic myelogeneous leukemia (CML) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with CML who responded to imatinib; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with lymphoma who were treated with atorvastatin. Therefore, we have described a new and highly sensitive method for determining oncoprotein expression and phosphorylation in clinical specimens for the development of new therapeutics for cancer.
Current methods of protein detection are insensitive to detecting subtle changes in oncoprotein activation that underlie key cancer signaling processes. The requirement for large numbers of cells precludes serial tumor sampling for assessing a response to therapeutics. Therefore, we have developed a nanofluidic proteomic immunoassay (NIA) to quantify total and low-abundance protein isoforms in nanoliter volumes. Our method can quantify amounts of MYC oncoprotein and B cell lymphoma protein-2 (BCL2) in Burkitt's and follicular lymphoma; identify changes in activation of extracellular signal-related kinases-1 (ERK1) and ERK2, mitogen-activated kinase-1 (MEK), signal transducer and activator of transcription protein-3 (STAT3) and STAT5, c-Jun N-terminal kinase (JNK) and caspase-3 in imatinib-treated chronic myelogeneous leukemia (CML) cells; measure an unanticipated change in the phosphorylation of an ERK2 isomer in individuals with CML who responded to imatinib; and detect a decrease in STAT3 and STAT5 phosphorylation in individuals with lymphoma who were treated with atorvastatin. Therefore, we have described a new and highly sensitive method for determining oncoprotein expression and phosphorylation in clinical specimens for the development of new therapeutics for cancer.
Cancer is frequently associated with the abnormal expression and phosphorylation of oncogenes [1] [2] [3] [4] . Specific hematopoietic tumors are frequently characterized by the discrete activation of specific oncogenes such as MYC [5] [6] [7] , BCL2 8, 9 and BCR-ABL (encoding breakpoint cluster region-Abelson) [10] [11] [12] [13] . Targeted inactivation of oncoproteins is emerging as a specific and effective therapy for cancer 14, 15 . The best known example of a targeted therapy is imatinib mesylate, a small molecule that inactivates several tyrosine kinases, including the BCR-ABL tyrosine kinase in CML [16] [17] [18] . Imatinib treatment results in tumor cell signaling changes in vitro, leading to cell death 19, 20 . In general, the ability to detect specific oncoproteins and their activation state is likely to be highly useful toward the development of new therapeutics as well as in monitoring the effectiveness of these treatments and in evaluating apparent therapeutic resistance 13, 21 .
To accurately measure oncoprotein expression and activation in limited clinical specimens, we have developed the NIA detection method, which combines isoelectric protein focusing and antibody detection. Here we show that we can use this new technique to quantify oncoprotein expression and phosphorylation in clinical specimens to precisely measure specific changes in phosphoisomers of oncoproteins in vitro and in vivo.
RESULTS

NIA detection of oncoprotein expression in clinical specimens
NIA incorporates isoelectric focusing of proteins followed by antibody detection of specific epitopes with chemiluminescence 22 . The chemiluminescent signal is rendered as a chemiluminescence isoelectropherogram (trace) of relative luminescence units (RLU) on the y axis versus isoelectric point (pI) on the x axis (Fig. 1a) . As little as 2 pg of recombinant MYC protein could be detected in 4 nl of sample per capillary (final capillary concentration 0.004-0.12 pg nl -1 ) at the expected pI of 5.6 with a linear response (Fig. 1b, R 
Concentrations of BCL2 could be detected over up to a three-log dynamic range at pI 6.7 (Fig. 1c , R 2 ¼ 0.9647). Therefore, NIA is highly quantitative and sensitive over a large dynamic range.
Next, we assessed the ability to detect oncoproteins in tumor cell lines both in vitro and in vivo. Previously, we described the generation of a conditional transgenic lymphoma model that uses the Tet-off system to regulate oncoprotein expression [23] [24] [25] . Briefly, the Tet-off system was used to conditionally regulate the expression of a human MYC or BCL2 transgene in lymphocytes. In the absence of doxycycline, the transgene is expressed, and in the presence of doxycycline, the transgene is turned off. In our tumor-derived cell lines, MYC anddifferent from the recombinant BCL2 described above because NIA is exquisitely sensitive to the cationic charge associated with the histidine tag of the recombinant protein. Our results elaborate how NIA can distinguish and measure oncoprotein expression from tumor cell lines.
To evaluate whether we could quantitatively detect oncoprotein expression in vivo, we inoculated conditional mouse tumor-derived cell lines into syngeneic mice. Examination of serial tumor samples by fine needle aspiration (FNA) confirmed that both MYC and BCL2 expression could be readily detected and quantified in vivo by NIA with results comparable to western blot analysis (Fig. 1d,e) . To determine oncoprotein expression in human tumors, we measured MYC and BCL2 abundance in four lymphomas and two benign lymph nodes. As expected, we detected increased MYC protein abundance in Burkitt's lymphoma and increased BCL2 protein abundance in follicular lymphoma compared with benign nodes (Fig. 2a) . Thus, NIA can reproducibly detect changes in oncoprotein expression even from limited clinical biopsy specimens from mouse or human tumors.
Our results suggested that we may be able to precisely quantify the amounts of oncoproteins in clinical specimens. We analyzed a set of 27 human specimens that included Burkitt's lymphoma, follicular lymphoma and benign lymph nodes, as well as normal peripheral blood mononuclear cells (set 1; Fig. 2b ). In this set, Burkitt's lymphoma samples expressed MYC at a level higher than all of the other sample groups (Mann-Whitney test, P o 0.0001). All of the Burkitt's lymphoma specimens had a MYC expression level higher than 0.2 RLU, compared with 11% of the follicular lymphoma specimens. 
Follicular lymphoma samples expressed significantly more BCL2 than all other sample groups (Mann-Whitney test, P o 0.0001); 89% of the individuals with follicular lymphoma had a BCL2 level higher than 0.06 RLU, compared with none of the individuals with Burkitt's lymphoma. BCL2 was detectable and quantifiable even in normal specimens (Fig. 2a,b) . NIA was quantitative enough to distinguish statistically significant differences in oncoprotein expression between lymphomas.
To validate our results, we next quantified MYC and BCL2 abundance in a new series of clinical specimens including seven Burkitt's lymphoma, eleven follicular lymphoma, nine diffuse large B cell lymphoma (DLBCL) and five marginal zone lymphoma specimens (set 2; Fig. 2b ). We confirmed that the MYC threshold of 0.2 RLU and the BCL2 threshold of 0.06 RLU were statistically significant for distinguishing Burkitt's from follicular lymphoma (Fisher's exact test, two-tailed: P ¼ 0.0498 and P ¼ 0.0474, respectively). We observed that two of nine DLBCL tumors overexpressed BCL2, and many tumors expressed high amounts of MYC (Fig. 2a,b) . In contrast, marginal zone lymphomas expressed a low mean level of 0.18 RLU MYC (Fig. 2a,b) . Hence, we found that in 44 of 49 tumor specimens the MYC and BCL2 expression differed when compared with normal controls.
NIA of oncoprotein phosphorylation in clinical specimens
A key feature of NIA is that it can be used to identify phosphorylated isoforms of a protein 22 . We detected ERK and distinct patterns of phosphoisomers in the normal and lymphoma specimens ( Supplementary Fig. 2a online). Next, we identified mitogen-activated protein kinase kinase-1 (MEK1) and MEK2 isomers ( Supplementary Figs. 2b and 3  online) . We performed the experiments in quadruplicate, and they were highly reproducible. We could detect as little as a 10% difference in abundance of specific phosphorylated isoforms of either ERK or AKT across the panel of specimens. Our results show that NIA is highly sensitive, reproducible and quantitative.
Next, we evaluated whether we could detect specific protein signaling changes in human tumors in response to targeted therapy. Treatment of the K562 human CML cell line with imatinib in vitro resulted in changes in the phosphorylation of STAT3, STAT5, JNK, MEK1 and MEK2 and an expected increase in activated caspase-3 associated with apoptosis ( Fig. 3 and Supplementary Fig. 4 online) . To facilitate a comparison with western blot results, we converted the data into a 'pseudo-blot' representation. In a pseudo-blot, the area under each NIA peak is represented as a band at the corresponding isoelectric point. By visualizing different isoforms we were able to identify that imatinib treatment was associated with a decrease in the expression of a specific ERK2 phosphoisomer ( Supplementary Fig. 5a online). Thus, NIA seemed to detect a unique signaling change in response to the targeted therapeutic agent, imatinib.
To evaluate whether we could identify changes in protein signaling in vivo in clinical specimens, we measured changes in oncoprotein signaling in the tumor cells in the peripheral blood of individuals with CML treated with tyrosine kinase inhibitors. All seven subjects who responded to tyrosine kinase inhibitor therapy showed a 54-100% decrease in a monophosphorylated ERK2 isoform ( Fig. 4a and Supplementary Fig. 5b,c) , whereas two subjects who were resistant to tyrosine kinase inhibitor therapy did not (Fig. 4b,c and Supplementary Table 1 online). Although basal ERK2 expression was not different ( Supplementary Fig. 6 online) , the relative fold change in ERK2 phosphorylation was different between subjects with CML who responded to therapy versus those who did not (unpaired t test, two-tailed P ¼ 0.0007). Thus, NIA may have identified a specific change in ERK phosphorylation that seems to be associated with a clinical response to effective therapy. Finally, we determined whether NIA could be used to serially monitor the response of a patient's tumor to a potential biologic response modifier in vivo. Recently, we described that atorvastatin treatment causes tumor regression associated with specific changes in oncoprotein signaling in a mouse model of lymphoma 26 . We have investigated whether atorvastatin has biological activity in humans with lymphoma. We found that patients treated with atorvastatin showed detectable decreases in phosphorylation of STAT3 and STAT5 after 8 d of treatment (Fig. 5) . Thus, we found that atorvastatin has unanticipated in vivo biologic activity against human lymphoma cells.
DISCUSSION
We have developed a highly sensitive and reproducible nanoscale technology to measure oncoprotein expression and phosphorylation and to identify the biological response to therapeutics. Our method detected as little as 2 pg of protein in as few as 4 nl of material over a three-log dynamic range. We quantified MYC and BCL2 oncoproteins as well as changes in cancer signaling proteins including ERK, MEK, JNK, STAT3 and STAT5 and apoptotic proteins such as caspase-3. The requirement of only a small amount of material enabled us to analyze serial samples of the same tumor in vivo, as we demonstrated in mouse models of lymphoma and in human tumor specimens; oncoprotein phosphorylation decreased in samples obtained from subjects with lymphoma before and after initiating treatment with imatinib or atorvastatin. We have shown that our method may have utility both for preclinical and clinical studies.
Our method enables the analysis of solid tissue specimens such as from tumor biopsies, as we illustrate through the analysis of lymphoma specimens. Thus, we could quantify differences in MYC and BCL2 oncoprotein expression in normal lymph tissue and different non-Hodgkin's lymphoma subtypes, including Burkitt's and follicular lymphomas. DLBCL and marginal zone lymphomas were not as readily distinguished, underlining that 
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lymphomas can have complex patterns of oncoprotein overexpression, and single proteomic measurements are not sufficient to distinguish most subtypes [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . The pathological diagnosis of lymphoma as well as of other tumor subtypes requires the combination of a number of analytical methods, including histological, biochemical and genetic techniques. Our approach has unique features that may complement these existing methodologies.
We were able to precisely measure oncoprotein isoforms that may be useful in the analysis of the therapeutic response in clinical tumor specimens. Previously, in vitro studies had suggested that treatment of CML tumor lines with imatinib results in decreased ERK phosphorylation 19, 20 . With our approach, we were able to identify specific and rare ERK isoforms in vivo in subjects with CML that would only be detectable with large amounts of tumor tissue for alternative techniques such as two-dimensional blots or mass spectrometry. Chargebased separation via isoelectric focusing of each protein isoform on the basis of its unique pI allowed simultaneous quantification of multiple isoforms of the same protein in relative proportions that could not have been detected a priori by western blot or FACS techniques. Our results would have been missed by conventional immunoassay or flow cytometric techniques, as commercially available immunoreagents for activated ERK are raised against dually phosphorylated ERK epitopes. Unlike FACS samples, NIA samples did not require processing into a single cell suspension, fixation or permeabilization. Furthermore, the decreased ERK2 phosphorylation correlated with the clinical response to tyrosine kinase inhibitors. Future studies will determine whether ERK2 phosphorylation will identify the 15% of patients in whom imatinib will eventually lose its effectiveness.
In addition, we were able to serially sample tumors in subjects with lymphoma for a biologic response to a therapeutic agent, atorvastatin. Our observations are consistent with our previous description that atorvastatin decreases STAT3 and STAT5 phosphorylation in mouse models of lymphoma 26 . One possible explanation for these findings is that atorvastatin treatment leads to the inhibition and activation of signaling molecules upstream of STAT3 and STAT5 (ref. 26). Our observations illustrate that NIA could be similarly used to determine the protein signature of and identify biomarkers for response to known and new therapeutic agents.
Our results demonstrate how a nanoscale proteomic technology can be used to uncover unanticipated changes in protein signaling in vivo. Small perturbations in the equilibrium between active and inactive protein isoforms may have marked effects on the biologic state of a cell 39 . Our approach provides a new technique that could be incorporated into preclinical and clinical studies to evaluate subtle shifts in protein abundance and modification that may be useful for the discovery of new drugs that target protein pathways and the identification of biomarkers of therapeutic efficacy.
METHODS
Nanofluidic proteomic immunoassay. We performed NIA experiments with a Firefly instrument (Cell Biosciences) 22 . Briefly, for each capillary analysis, we diluted 4 nl of 10 mg ml -1 lysate to 0.2 mg ml -1 in 200 nl HNG (20 mM HEPES pH 7.5, 25 mM NaCl, 0.1%, 10% glycerol, Sigma Phosphatase Inhibitor Cocktail 1 diluted 1 in 100 and Calbiochem Protease Inhibitor diluted 1 in 100). We added 200 nl sample mix containing internal pI standards. The Firefly system first performed a charge-based separation (isoelectric focusing) in a 5-cm-long, 100-micron-inner-diameter capillary. We calculated predicted pIs with Scansite 40 . We ran each sample on a panel of different pH gradients (pH 3-10 and pH 2-11) to optimize the resolution of different peak patterns. After separation and photo-activated in-capillary immobilization, we detected proteins with antibodies. We detected MYC protein with the 9E10, OP-10 mouse monoclonal antibody that recognizes human MYC (Calbiochem). We detected BCL2 protein with the clone 124 mouse monoclonal antibody that recognizes human BCL2 (Dako Laboratories) and the clone 6C8 monoclonal hamster antibody that recognizes human BCL2 (Becton-Dickinson). We detected total ERK1 and ERK2 protein with a rabbit polyclonal antibody that recognizes mouse and human ERK1 and ERK2 (Upstate). We detected phospho-ERK1 and phospho-ERK2 protein with a mouse monoclonal antibody that recognizes both mouse and human phospho-ERK1 and phospho-ERK2 (Cell Signaling). We also used antibodies to activated caspase-3 (Cell Signaling), MEK1 (Upstate), phospho-MEK1 (Novus), MEK2 (Abcam), phospho-STAT3 (Cell Signaling), phospho-STAT5 (Cell Signaling), phospho-JNK (Cell Signaling) and heat shock protein-70 (HSP-70; Novus).
Nanofluidic proteomic immunoassay peak area quantification. We quantified the peaks with peak analysis software. We manually selected the start and end of each peak and a flat baseline. We calculated the area of each peak by dropping verticals to the baseline at the peak start and end and summing the area between the start and endpoints. NIA has previously been shown to be able to discriminate between and to quantify phosphorylated and unphosphorylated isoforms of ERK in a single sample with a total ERK antibody 22 . The areas under different peaks within a single tracing represented various ERK isoforms. To calculate the percentage of monophosphorylated ERK2 (identified here as peak 3), we divided the area under peak 3 by the sum of the area under the total ERK peaks. We ran samples in duplicate.
Nanofluidic proteomic immunoassay pseudoblot generation. We created the pseudoblots by a linear mapping of the signal intensity to a grayscale image. Each pseudoblot lane is representative of a single capillary and consists of horizontal bands corresponding proportionally to the signal present. Absence of signal is white, whereas increasing signal is seen as an increasing dark band. It should be noted that what is seen as a single band of protein in a size-based western blot can appear as either a single band on an NIA pseudoblot or, when multiple charged isomers of the protein are present, as multiple bands on an NIA pseudoblot.
Human tumor samples. We obtained tissues from subjects and banked them per Stanford University Institutional Review Board-approved protocols. We obtained informed consent from all subjects. We isolated CML and CLL cells from total blood by Ficoll separation, resuspended them in heat-inactivated FBS plus 10% DMSO and stored them in liquid nitrogen. We thawed tumor cells stored in liquid nitrogen at 37 1C into prewarmed PBS and washed them once in PBS immediately before use. We obtained four previously banked follicular lymphomas viably cryopreserved in a single cell suspension. We also obtained previously banked Burkitt's lymphomas, follicular lymphomas, marginal zone lymphomas, T cell acute lymphoblastic leukemia and nonmalignant lymph nodes frozen in optimal tissue-cutting blocks from the Stanford Hematology Division Tissue Bank.
Data and statistical analyses. We did NIA Multipeak fitting and peak area calculations with Peak Fit version 4.11 (Systat Software), using Gaussian peaks with variable widths, as previously described 22 . To obtain R 2 correlation coefficients, we calculated the best-fit line by linear regression with IGOR Pro version 5.03 (Wavemetrics). We compared NIA quantifications of MYC and BCL2 abundance to the relative intensity of respective quantified western blot bands by Pearson correlation. We used the paired t test (two-tailed) to analyze the percentage of phospho-ERK2 peak 3 before and during treatment. We performed the Mann-Whitney rank-sum test on the panels of clinical specimens with Prism version 4.0 (GraphPad). We also used Prism version 4.0 for Fisher's exact test (two-tailed) analysis of contingency table data for MYC and BCL2.
Normalization of nanofluidic proteomic immunoassay data. We normalized NIA data in a similar fashion to normalization of traditional western blots or other molecular biology assays. We used HSP-70 as a 'housekeeping' protein for NIA normalization. We calculated RLU by dividing the measured peak area for the protein of interest by the measured peak area for HSP-70 and expressed it as a percentage. Across different experiments, we used a standardized lysate control for calibration of instruments and runs.
Additional methods. Detailed methodology is described in the Supplementary Methods online.
Note: Supplementary information is available on the Nature Medicine website.
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